Ovid Therapeutics (OVID) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Ovid Therapeutics

NasdaqCM•Healthcare•Biotechnology

$2.80+0.02(0.01%)Market closed

Market Cap

$529.17M

P/S

334.3x

P/B

2.5x

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

How this company scores

AverageMetricSide Score: 41/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Cash & Earnings Quality (8/25).

Profitability9/25

Growth9/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality8/25

Strengths

Interest easily coveredCash-backed earningsProfit converts from growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 1.8x5y range 1.8x – 1.8x

P/S · 334.3x5y range 1.0x – 1477.8x

Currently above its 20-quarter median.

P/B · 2.5x5y range 0.4x – 2.8x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $529.17M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $1.58M
Q. Revenue: $733,000
TTM EBITDA: $-58.24M
TTM Op. Income: $-58.36M
Q. Op. Income: $-15.70M
TTM Net Income: $-34.49M
Q. Net Income: $-15.01M
EPS: $-0.08
Shares Out.: $197.45M

$1.58M in TTM revenue declined 76.2% YoY, reaching $733,000 last quarter. TTM EBITDA of $-58.24M and TTM operating income of $-58.36M show growth is flowing through to the bottom line. However, net income is negative at $34.49M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 2 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 97.8%
EBITDA Margin: -2139.4%
Op. Margin: -2141.6%
Net Margin: -2047.6%

Op. margin of -2141.6% is down 2060.7% YoY — costs are rising relative to revenue. Net margin at -2047.6% and gross margin of 97.8% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 2548% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 334.3x
P/B Ratio: 2.5x

P/S of 334.3x and P/B of 2.5x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $231.97M
Cash: $11.33M
Long-Term Debt: N/A
Book Value: $209.89M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-17.59M
TTM Free Cash Flow: $-54.77M
FCF Margin: -3460.1%
FCF / Net Income: 1.6

TTM FCF of $-54.77M on $-17.59M in operating cash flow. The FCF / Net Income ratio of 1.6x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 3 consecutive quarters — a weakening trend.